Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis (Q33391708)

26 July 2017

title

Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

0 references

1 reference

1 reference

Yi Qian

1 reference

26 July 2017

Jing Pan

1 reference

26 July 2017

Xiaodong Zhou

1 reference

26 July 2017

Peter Weiser

1 reference

26 July 2017

Hong Lu

1 reference

26 July 2017

Lijuan Zhang

1 reference

26 July 2017

publication date

1 January 2010

1 reference

Progress in Molecular Biology and Translational Science

26 July 2017

published in

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

395-421

1 reference

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

1 reference

7 January 2021

Thrombin generation and heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Heparin-induced thrombocytopenia: a historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Contaminated heparin associated with adverse clinical events and activation of the contact system

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Outbreak of adverse reactions associated with contaminated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Anaphylactic transfusion reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Current understanding of contrast media reactions and implications for clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

The plasma kallikrein-kinin system: its evolution from contact activation

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Activation of factor XII and prekallikrein with cholesterol sulfate.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Activation of factor XII and prekallikrein with polysaccharide sulfates and sulfatides: comparison with kaolin-mediated activation

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Inactivation of kallikrein in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Nanoparticle-induced platelet aggregation and vascular thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Kallikrein activates prothrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Kininogens are antithrombotic proteins In vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Roles of the kallikrein/kinin system in the adaptive immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Roles for the Kallikrein-Kinin System in Inflammatory Exudation and Pain: Lessons From Studies on Kininogen-Deficient Rats

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

The nature of the stable blood clot procoagulant activities

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Hyperglycaemia and cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Anticoagulant use in patients with chronic renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Pulmonary and thrombotic manifestations of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

The approach to heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

Oversulfated chondroitin sulfate is not the sole contaminant in heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993017-2

7 January 2021

10.1016/S1877-1173(10)93017-2

Identifiers

DOI

1 reference

26 July 2017

1 reference